The estimated Net Worth of Christopher R. Loose is at least $7.53 Million dollars as of 27 July 2023. Mr. Loose owns over 2,717 units of Frequency Therapeutics Inc stock worth over $55,095 and over the last 5 years he sold FREQ stock worth over $4,581,632. In addition, he makes $2,894,520 as Co-Founder and Chief Scientific Officer at Frequency Therapeutics Inc.
Christopher has made over 33 trades of the Frequency Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,717 units of FREQ stock worth $1,359 on 27 July 2023.
The largest trade he's ever made was selling 24,000 units of Frequency Therapeutics Inc stock on 14 December 2020 worth over $889,680. On average, Christopher trades about 6,017 units every 29 days since 2019. As of 27 July 2023 he still owns at least 183,650 units of Frequency Therapeutics Inc stock.
You can see the complete history of Mr. Loose stock trades at the bottom of the page.
Dr. Christopher R. Loose Ph.D. serves as Co-Founder, Chief Scientific Officer of the Company. Prior to our Company, Dr. Loose co-founded Semprus with Mr. Lucchino and Dr. Langer and served as its Chief Technology Officer from June 2007 until its acquisition by Teleflex in June 2012. At Semprus, he led the technology team in the development through regulatory clearance of medical products designed to reduce infection and clotting. Prior to Semprus, Dr. Loose worked as a chemical engineer at Merck Research Labs. In 2011, Dr. Loose was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. Since 2014, Dr. Loose has served as an Associate Professor Adjunct of Urology at the Yale School of Medicine. Dr. Loose is also the Executive Director of Yale University’s Center for Biomedical and Interventional Technology. Dr. Loose holds a Ph.D. in Chemical Engineering from MIT and a BSE in Chemical Engineering summa cum laude from Princeton University.
As the Co-Founder and Chief Scientific Officer of Frequency Therapeutics Inc, the total compensation of Christopher Loose at Frequency Therapeutics Inc is $2,894,520. There are 1 executives at Frequency Therapeutics Inc getting paid more, with David Lucchino having the highest compensation of $7,364,600.
Christopher Loose is 39, he's been the Co-Founder and Chief Scientific Officer of Frequency Therapeutics Inc since 2016. There are 17 older and no younger executives at Frequency Therapeutics Inc. The oldest executive at Frequency Therapeutics Inc is Timothy Barberich, 72, who is the Independent Director.
Christopher's mailing address filed with the SEC is C/O FREQUENCY THERAPEUTICS, INC., 75 HAYDEN AVE, SUITE 300, LEXINGTON, MA, 02421.
Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer, and Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
Frequency Therapeutics Inc executives and other stock owners filed with the SEC include: